HMG (Menopur / Pergonal)
Human Menopausal Gonadotropin – urinary-extracted FSH + LH 75/75 IU mixture. In AAS-PCT: full HPG axis restart (Sertoli FSH support too, not just Leydig LH like HCG). Pergonal withdrawn 2005, Menopur modern alternative. Cross-frame: future peptide library will add `hmg-peptid`.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS HMG (MENOPUR / PERGONAL)?
Detailed overview
HMG (Human Menopausal Gonadotropin) is a glycoprotein mixture purified from postmenopausal female urine, containing approximately 75 IU follicle-stimulating hormone (FSH) + 75 IU luteinizing hormone (LH) per standard ampoule (1:1 ratio). The clinical history of HMG can be divided into two eras: (1) **Pergonal era** (1962-2005) – led by Bruno Lunenfeld, an Israeli endocrinologist, urine collected from menopausal nuns of the Vatican Catholic order (the 1962 first clinical use traces to Sisters Carmela and Donatella), manufactured by Serono Pharmacia, indication ovulatory infertility. (2) **Menopur era** (2002 EMA approval → today) – Ferring higher-purity urinary-extracted product, replacing Pergonal due to vCJD risk reduction. **AAS-PCT context**: HMG's unique value is that, unlike HCG, it supplies BOTH gonadotropins (FSH + LH) → full HPG axis restart (not just Leydig stimulus like HCG, but also Sertoli-cell FSH stimulus). Indication in AAS users: after long-cycle/hard-suppression, when the user's own pituitary FSH still isn't secreting enough Sertoli support → accelerated spermatogenesis recovery. **Cross-frame note**: this is the `-perf` suffix entry; the future peptide library batch will add the `hmg-peptid` entry (fertility-clinic framing – IVF male-factor protocol, IUI/COS ovulation induction context). WADA-banned year-round (S2 Peptide Hormones).
Mechanism
Urinary-extracted FSH (75 IU) + LH (75 IU) mixture – Sertoli-FSHR + Leydig-LHCGR receptor double-stimulus
Dosing (PCT)
75-150 IU EOD × 2-4 weeks
Half-life
FSH ~24-36 h / LH ~20 h (mixed component decay)
Onset
Test rise 5-10 days, spermatogenesis restart 4-8 weeks
Legal status
EMA Rx Menopur (Ferring 2002), USA FDA Rx Menopur (2005), WADA S2 (banned)
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Estrogen rebound: FSH+LH stimulation raises endogenous testosterone and secondarily E2, at higher doses (>150 IU EOD) causing gynecomastia, water retention and mood swings.
- Injection-site reactions (SC/IM): pain, redness, swelling, itching, rarely haematoma or sterile abscess at the injection site.
- Hypersensitivity and allergic reactions to the urine-derived protein: urticaria, rash, rarely severe systemic (anaphylactic) reactions.
- Headache, fatigue, abdominal discomfort and bloating, nausea – common, dose-dependent, usually mild gonadotropin side effects.
- Testicular tenderness and transient enlargement from the dual Leydig+Sertoli stimulus; risk of receptor downregulation with prolonged (>6 weeks) monotherapy.
- Acne and oily skin, mood irritability secondary to rising endogenous androgen levels.
- Thromboembolic risk (rare): the classic gonadotropin class warning notes possible venous/arterial thrombosis, especially with congenital or acquired thrombophilia.
Contraindications · 7
- Known hypersensitivity to HMG, menotropins or any excipient (urine-derived protein sensitization).
- Hormone-dependent tumors or their suspicion: testicular, prostate, pituitary or hypothalamic tumor – gonadotropin stimulation may promote their progression.
- Infertility of a cause on which HMG is ineffective (Klinefelter syndrome, Y-chromosome deletion, primary testicular failure) – no therapeutic benefit.
- Untreated or poorly controlled endocrine disorder (thyroid, adrenal dysfunction, hyperprolactinemia) – must be corrected first.
- Pre-pubertal males and childhood – not indicated in this user context.
- Active thromboembolic disease or severe thrombophilia – relative contraindication due to the gonadotropin class thrombosis risk, requires close monitoring.
- Concurrent exogenous TRT (chronic testosterone) – Leydig cells are suppressed, HMG stimulation is ineffective and pointless in this context.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism.
Zheng Y, Bai HZ, Zhao GC
Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism.
Schaison G, Young J, Pholsena M, Edery M, Touraine P, Lahlou N
Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone
Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E.
Telegram
Have a question about HMG (Menopur / Pergonal)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.